ibrutinib
abbvie,janssen
['biotec']
#asco22: imbruvica keeps aggressive blood cancer at bay for 6+ years, but misses the mark in overall survival #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #pharma #healthcare #biotech 
Strategy & Competitive Marketing | Digital & Social Pharma | Life Sciences Investment | Cell & Gene Therapy | Vaccines